Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q3 2022
Net profit, assets, equity and cash flow for Q3 2022, against the same period a year earlier, from the published financial statements.
Net profit58.1 millionEGP
Total assets754 millionEGP
Shareholders' equity419 millionEGP
Operating cash flow2.73 millionEGP
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q3 2022 was about 58.1 million EGP.
- Total assets at the end of Q3 2022 were about 754 million EGP, and shareholders' equity about 419 million EGP.
- Operating cash flow for Q3 2022 was positive at 2.73 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit58.1 million——
Gross profit173 million——
Total assets754 million——
Total liabilities336 million——
Shareholders' equity419 million——
Total liabilities and equity754 million——
Operating cash flow2.73 million——
Investing cash flow-1.75 million——
Financing cash flow-15.28 million——
Net change in cash-14.3 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy